A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus : a gynecologic oncology group study

AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there d...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1991-02, Vol.9 (1), p.93-94
Main Authors: SLAYTON, R. E, BLESSING, J. A, CLARKE-PEARSON, D
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Aziridines - adverse effects
Aziridines - therapeutic use
Benzoquinones - adverse effects
Benzoquinones - therapeutic use
Biological and medical sciences
Drug Evaluation
Female
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Sarcoma - drug therapy
Uterine Neoplasms - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00194555